-dependent ad-snakes of Viperidae and Crotalidae families (2). Studies hesion of platelets to collagen was diminished in a of these snake venoms have revealed that snake venom dose-dependent manner, while the glycoprotein IIb/ proteins affect platelet functions markedly by acting IIIa-mediated platelet-fibrinogen interaction was un-as either inducers or inhibitors (3). Of these proteins, affected. When collagen was pretreated with crovi-the most prominent inducers are trimucytin and agdisin and followed by three washes with phosphate-gretin which were isolated from Trimeresurus mucrosbuffered saline, the antiadhesion activity of crovidisin quamatus (Taiwan habu snake) and Calloselasma rhowas unaffected. In addition, collagen fibers emitted dostoma (Malayan pit viper) venoms, respectively. fluorescence after incubation with fluorescein isothio-Both inducers cause platelet activation and aggregacyanate-conjugated crovidisin, indicating that crovition through the activation of endogenous phospholidisin binds directly to collagen fibers. In conclusion, pase C by acting as GPIa/IIa agonists (4, 5). On the crovidisin blocks the interaction between platelets other hand, disintegrins are a group of low-molecularand collagen fibers through its binding to collagen fiweight proteins occurring in various snake venoms (6) and have been named according to their inhibitory ac-1
Antiplatelet activity of each fraction was assessed on thrombin-and which has been demonstrated to play an important role collagen-induced aggregation of human washed platelets. Fractions in matrix-cell interaction (10) . The study of these that selectively inhibited collagen-induced platelet aggregation were venom proteins not only enriches our understanding of pooled and lyophilized and a DEAE Sephadex A-50 column (1.6 1 the mechanism underlying the detrimental symptoms 40 cm) was employed for the further purification with a buffer gradient from 0.2 M ammonium acetate (pH 8.2) to 0.8 M ammonium following snakebite (11) , but also provides useful tools acetate (pH 6.4) at a flow rate of 15 ml/h. Crovidisin was finally for exploring the mystery of life science (12) as well as purified to homogeneity by HPLC using a reverse-phase Ultrapore opening a new avenue for developing antithrombotic C8 column (0.46 1 25 cm, Beckman) equilibrated with solution A agents (13) .
(0.1% TFA in water, v/v) at a flow rate of 1 ml/min, and a gradient Recently, some inhibitors which specifically interfere of solution B (a mixture of water (20%), acetonitrile (80%), and TFA (0.1%), v/v) from 25 to 80% in 40 min was used to elute the applied with collagen-mediated platelet functions have been proteins. Protein eluates were monitored by UV detector at 280 nm found in snake venoms, including a 50-kDa protein and dried with a SpeedVac concentrator. After reconstituting these from Bothrops atrox (14) , jararhagin from Bothrops jar-proteins with distilled water, their antiplatelet activities were subsearaca (15) , and catrocollastatin from Crotalus atrox quently tested. (16) . The action mechanism of jararhagin has been re-SDS/PAGE. The molecular weight of crovidisin was estimated by SDS/PAGE on a 12% polyacrylamide gel following the method ferred to be a collagen receptor (GPIa/IIa) antagonist, described by Laemmli (20) in the presence or absence of reducing whereas the other two have not been documented. Our agent, b-mercaptoethanol (4%, v/v). Following electrophoresis, prolaboratory found that snake venom of Crotalus viridis tein bands on the slab gel were stained with Coomassie blue R-250 possessed an inhibitory activity on platelet aggregation (0.1%). elicited by various inducers and this inhibitory activity S-carboxymethylation of crovidisin. This reaction was carried out was mainly attributed to the action of crotavirin, a by adding 20 ml of iodoacetic acid (1 M in H 2 O) to the reduced protein (800 mg in 1 ml of 8 M urea, 15 mM Tris-HCl, pH 8.5, and 20 mM member of disintegrins, by acting as a GPIIb/IIIa anb-mercaptoethanol). The reaction mixture was incubated 2 min at tagonist (17) . Concurrently, we also found that there 25ЊC in the dark and the modified protein was isolated free of rewas another platelet aggregation inhibitor in this agents by a Sephadex G-10 column (1 1 30 cm). venom. This principle inhibited the platelet aggrega- to study its mechanism of action.
at room temperature and subsequently quantified by reverse-phase HPLC by comparing with amino acid standards coupled with PITC under similar conditions.
MATERIALS AND METHODS
Preparation of human platelet suspension. Human platelet susMaterials. Lyophilized crude venom powder of C. viridis was purpension was prepared following the protocol of Mustard et al. (22) . chased from Latoxan (Rosans, France). Molecular weight standards Blood samples obtained from healthy adults who did not receive for SDS/PAGE and gels used for chromatography, including Sepha-medication in the past 2 weeks were anticoagulated with acid citrate/ dex G-100, G-10, and DEAE Sephadex A-50, were obtained from dextrose and centrifuged at 150g at room temperature (25ЊC) for 9 Pharmacia (Uppsala, Sweden). Bovine thrombin was obtained from min to obtain platelet-rich plasma (PRP). After being incubated with Parke Davis (Detroit, MI). Sodium arachidonate, Fura-2/AM, type I heparin (5 units/ml) and prostaglandin E 1 (1 mM) for 5 min at room collagen (bovine achillis tendon), human fibrinogen, prostaglandin temperature, platelets of PRP were pelleted by centrifugation at 500g E 1 , ADP, apyrase, firefly lantern extract (mixture of luciferin and at room temperature for 7 min and subsequently washed two times luciferase), and BSA 3 were obtained commercially from Sigma Chem-with Tyrode solution (NaH 2 PO 4 , 0.4 mM; NaCl, 136.9 mM; KCl, 2.7 ical Co. (U.S.A.). Heparin was from Novo Nordisk (Bagsvaerd, Den-mM; NaHCO 3 , 11.9 mM; CaCl 2 , 2 mM; MgCl 2 , 1 mM; BSA, 3.5 mg/ mark) and fluorescence dyes, BCECF/AM, and FITC were purchased ml; pH 7.35). Heparin (5 units/ml), prostaglandin E 1 (1 mM) and from Molecular Probes, Inc. (U.S.A.). Trifluoroacetic acid (TFA) and apyrase (0.5 units/ml) were included in the first suspension medium, acetonitrile were from Merck (U.S.A.). Iodoacetic acid and urea were while the last wash contained only apyrase (0.5 units/ml). Platelet commercially obtained from Fluka Chemical Co. (Japan) and Kanto count was adjusted to be 3.75 1 10 8 platelets/ml for aggregation Chemical Co. (Japan), respectively. Monoclonal antibodies, 6F1 assay. BCECF-loaded platelet suspension was prepared basically ac-(against glycoprotein Ia/IIa) (18) and 7E3 (against glycoprotein IIb/ cording to the procedure described above. To uptake BCECF/AM, IIIa) (19) ) containing 5 mg/ml of grins, was purified from C. viridis snake venom following the protocol BCECF/AM and incubated at 37ЊC for 30 min. Dye-loaded platelets described by Liu et al. (17) .
were pelleted and washed two times with the modified Tyrode soluPurification of crovidisin from Crotalus viridis venom. Crude tion as described above and prostaglandin E 1 (2 mM) was included in venom powder (0.1 g) was first fractionated by a Sephadex G-100 all processes. Finally, BCECF-loaded platelets were suspended in column (1.6 1 70 cm) eluted with 0.01 M ammonium bicarbonate. modified Tyrode solution containing prostaglandin E 1 (2 mM) and adjusted to be 3 1 10 8 platelets/ml for adhesion assay. Measurement of platelet aggregation, ATP release. Platelet aggregation was measured with a lumi-aggregometer (Payton Scientific) 3 Abbreviations used: GP, glycoprotein; BSA, bovine serum albumin; TFA, trifluoroacetic acid; PITC, phenyl isothiocyanate; BCECF/ turbidimetrically (23) . Mixtures (total 500 ml) of 400 ml of human platelet suspension (3.75 1 10 8 platelets/ml), test sample, and an AM, 2,7-bis(2-carboxyethyl)-5-(and -6-)carboxyfluorescein, acetoxymethyl ester; FITC, fluorescein isothiocyanate; PBS, phosphate-buffappropriate volume of Tyrode solution have been incubated at 37ЊC for 3 min under a stirring condition (900 rpm) prior to the addition ered saline; PRP, platelet-rich plasma.
of inducers. The extent of aggregation was expressed as the increase of light transmission at 6 min after the addition of aggregation inducer. Percentage aggregation of platelets was calculated as the final extent of aggregation relative to that of control (as 100% aggregation). ATP release reaction was monitored by bioluminence change (24) with 10 ml mixture of luciferin and luciferase.
Measurement of the intracellular Ca
2/ level. The concentration of intracellular free Ca 2/ was determined using a fluorescent probe, Fura-2, according to the method of Pollock and Rink (25). Fura-2-loaded platelets were prepared essentially as the washed platelets except washing with Ca 2/ -free Tyrode solution and allowed platelets to uptake Fura-2/AM (1 mM) for Chromatography of crude venom of Crotalus viridis snake tion of platelets caused by collagen in the presence of vehicle, crovi-on a Sephadex G-100 column. Crude venom powder (0.1 g) was fracdisin, or crotavirin was stopped by adding indomethacin (50 mM) tionated on a Sephadex G-100 column (1.6 1 180 cm) eluted with and EDTA (2 mM) at 6 min following the addition of collagen. After 0.01 M ammonium bicarbonate at a flow rate of 6 ml/h and absorbance centrifugation, the content of thromboxane B 2 , a stable metabolite (at 280 nm) of the eluent was continuously recorded (rrr). An aliquot of thromboxane A 2 , in the supernatant was determined by a EIA kit (10 ml) of each fraction was assayed for antiplatelet activity on colla-(Cayman Chemical Co.).
gen (10 mg/ml, l) and thrombin (0.2 U/ml, ᮀ)-induced platelet aggrePlatelet adhesion assay. This assay was carried out according to gation. the protocol described by Santoro (27) with a minor modification. Matrix, type I collagen (100 mg/ml) in acetic acid (25 mM) or fibrinogen (100 mg/ml) in phosphate-buffered saline (PBS), was coated onto solution B (a mixture of water (20%) and acetonitrile (80%)) for 40 plate wells (Falcon, 96-well) for 4 h at room temperature (25ЊC) and min at a flow rate of 1 ml/min. subsequently blocked with BSA (5 mg/ml) solution for 1 h. The coated wells were rinsed with PBS (100 ml) for three times and then an Peptide sequencing. Amino acid sequences of some tryptic pepaliquot of 50 ml of BCECF-loaded platelet suspension (3 1 10 8 /ml) tides were determined by using an Applied Biosystems 477A gaspretreated with vehicle, crovidisin, or monoclonal antibodies for 10 pulsed liquid-phase sequencer equipped with an on-line 120A PTHmin was added into matrix-coated wells. Platelets were allowed to amino acid analyzer. settle onto collagen or fibrinogen for 10 and 20 min at room temperature (25ЊC), respectively. Nonadherent platelets were removed by RESULTS aspiration and a gentle wash with 200 ml of the modified Tyrode solution. Adherent platelets were lysed with 100 ml of Triton X-100 Isolation and Characterization of Crovidisin (1%) and the plate was subsequently subjected to a fluorescent reader (Cytofluor 2300, Millipore) equipped with excitation and emission
Crude venom of C. viridis was first fractionated by filters centered at 485 and 530 nm, respectively, for the measurement gel filtration on a Sephadex G-100 column and abof fluorescence intensity. Percentage adhesion was calculated acsorbance of the eluent at 280 nm was continuously cording to a regression plot of fluorescence intensity versus the fixed monitored. Platelet aggregation in response to collagen number of BCECF-loaded platelets (ranged from 1.5 to 100% of total and thrombin was found to be inhibited by aliquot (in added cells) in 100 ml of Triton X-100 (1%, v/v). 10 ml) from fractions 22 to 27, in which a member of
FITC conjugation of proteins and their interaction with collagen.
disintegrin family, termed crotavirin, has been demonConjugation of crovidisin and BSA with FITC was carried out according to the procedure described by Liu et al. (28) . FITC conjugastrated to account for this inhibitory action (17) . In tion did not affect crovidisin's inhibitory activity. Similar conjugating addition, fractions that exhibited a selective inhibitory efficacy was obtained with crovidisin and BSA. Prior to the binding activity on collagen-induced platelet aggregation (Fig. assay, a 96-well plate was precoated with collagen as described 1) were pooled, lyophilized, and further purified by anabove. Various concentrations of FITC-crovidisin or FITC-BSA (in PBS) were allowed to interact with coated collagen at room temperaionic exchanger (DEAE-Sephadex A-50). Fractions ture for 10 min, followed by three washes with PBS and subsequently (ranging from 83 to 100) that inhibited collagen (10 mg/ the plates were subjected to fluorescence measurement by a fluoresml)-induced platelet aggregation (Fig. 2) were desalted cent reader (Cytofluor 2300). The fluorescence intensity of collagen and finally purified by reverse-phase HPLC. Using a fibers was measured using excitation and emission wavelengths at linear gradient of acetonitrile, the active principle was 485 and 530 nm, respectively. The fluorescence image of the collagen fibers was also taken by a Nikon fluorescent microscope equipped eluted at the retention time of 36 min (Fig. 3) and SDS/ with a camera.
PAGE of this protein showed a single band with a moCleavage of S-carboxymethylated crovidisin with trypsin. Trypsin lecular weight of 53 and 62 kDa, respectively, under (TPCK treated, Worthington Biochemical Corp.) digestion of the nonreduced and reduced conditions (Fig. 4) . This spemodified crovidisin was carried out at pH 8.8 for 2 h at 37ЊC with cific inhibitor of collagen-induced platelet aggregation an enzyme to protein ratio of 1:50 by weight and tryptic peptides was named as crovidisin. Amino acid analysis revealed were isolated by a reverse-phase HPLC using a C18 column (LiChrospher WP 300, Merck) with a linear gradient from 0 to 60% of that crovidisin is a glycine-and lysine-rich protein (Ta- and its potency depended on the concentration of collagen used for triggering aggregation (Fig. 5) . IC 50 of croble I) and its composition was found to be similar to vidisin on platelet aggregation elicited by 5 and 10 mg/ that of another snake (Crotalus atrox)-derived inhibiml of collagen were estimated to be 0.17 and 0.47 mM, tor, catrocollastatin, whose amino acid sequence has been deduced from its cDNA (16) . Note. Amino acids are expressed as three-letter abbreviations and the nearest integer of each amino acid residue is shown. Asparagine with solution A (0.1% TFA in H 2 O, v/v) and proteins were eluted by an increasing gradient of acetonitrile as indicated (rrr) of solution and glutamine were determined as aspartic acid and glutamic acid, respectively. ND, not determined. The amino acid composition of B (mixture of 20% H 2 O and 80% acetonitrile containing 0.1% TFA). Crovidisin was eluted at 36 min (*).
Effect of Crovidisin on the Aggregation and ATP
catrocollastin was taken from the sequence deduced from cDNA (16).
respectively. At the concentration (1 mM) that completely inhibited collagen (10 mg/ml)-induced platelet aggregation, crovidisin did not exert any significant effect on platelet aggregation caused by ADP, thrombin, and sodium arachidonate (Fig. 6 ). Collagen- induced   FIG. 6 . Effects of crovidisin on platelet aggregation caused by collagen, thrombin, sodium arachidonate, and ADP. After pretreatment of platelet suspension with 1 mM crovidisin (/) for 3 min, various inducers, including collagen (10 mg/ml), thrombin (0.2 U/ml), sodium arachidonate (AA, 100 mM), or ADP (20 mM), were added into the platelet suspension to trigger platelet aggregation. Human fibrinogen (200 mg/ml) was added in the case of ADP-induced platelet aggregation. One of three similar experiments is represented.
ATP release was also dose-dependently attenuated by crovidisin and completely abolished when platelet aggregation was blocked (data not shown). Pretreatment of platelets with crovidisin for a longer period (10 min) did not cause a higher degree of inhibitory activity to be attained (data not shown). Furthermore, when platelets failed to aggregate in response to collagen (10 mg/ml) in the presence of crovidisin (1 mM), a further addition of collagen overcame the inhibitory activity of crovidisin and elicited a full aggregation (data not shown).
Effect of Crovidisin on Thromboxane Formation of Platelets Caused by Collagen
Thromboxane A 2 formation is a landmark of collageninduced activation of platelets. Thromboxane B 2 , a stable metabolite of thromboxane A 2 , in the suspension of platelets in response to collagen (10 mg/ml) was measured in the presence or absence of inhibitors crovidisin (1 mM) and crotavirin (0.5 mM), a glycoprotein IIb/IIIa antagonist (17) . Our results showed that only negligible amount of thromboxane B 2 (0.35 { 0.047 ng/ml, n Å 4) was detected in the unstimulated platelet suspension, but collagen (10 mg/ml) markedly elevated the thromboxane B 2 content (68.4 { 6.5 ng/ml, n Å 4). Crovidisin completely blocked collagen-induced thromboxane B 2 formation (0.52 { 0.14 ng/ml, n Å 4; 99% inhibi- activity was completely abolished by crovidisin (1 mM) but not affected by crotavirin (0.5 mM) (Fig. 7) .
Effect of Crovidisin on Platelet Adherence to diminished in the presence of increasing dose of croviImmobilized Collagen and Fibrinogen
disin, and the maximal effect (about 80% inhibition) of crovidisin was achieved at 3.3 mM. After pretreatment In order to see whether crovidisin prevents plateletof collagen fibers with crovidisin for 10 min followed collagen interaction, platelets were preloaded with a by three washes with PBS, the interaction between fluorescent dye, BCECF, and adhesion of platelets to platelets and collagen remained defective. On the other collagen was assessed. The adhesion of BCECF-loaded hand, GPIIb/IIIa complex-mediated platelet-fibrinoplatelets to coated collagen or fibrinogen was detergen interaction was not significantly affected by crovimined in the modified Ca 2/ -free Tyrode solution condisin, even at concentration up to 6.7 mM (data not taining 2 mM MgCl 2 and 2 mM PGE 1 . As shown in Fig. shown). Unlike crovidisin, crotavirin, a member of dis-8, adhesion of platelets to collagen was progressively integrins, inhibited the adhesion of platelets to fibrinogen (96% inhibition) and only slightly affected the adhesion of platelets to collagen (11% inhibition) at the concentration of 4.4 mM. 6F1 and 7E3 are two murine monoclonal antibodies raised against platelet membrane GPIa/IIa and GPIIb/IIIa, respectively. At 20 mg/ ml, 6F1 blocked the adhesion of BCECF-loaded platelets to immobilized collagen to an extent of 60% with only a slight effect on the interaction between platelets and fibrinogen (10% inhibition). Conversely, 7E3 (20 mg/ml) completely blocked platelet-fibrinogen interaction (97% inhibition), exhibiting only a slightly inhibitory activity (13% inhibition) on platelet-collagen interaction. -dependent adhesion of platelets to collagenlowed by three washes with PBS, collagen fibers emitcoated surface (100 mg/ml, ᮀ) was determined in the presence of ted fluorescence (Fig. 9) and their fluorescence intenvehicle or various concentrations (ranging from 0.83 to 6.7 mM) of crovidisin. Concurrently, platelet adherence to crovidisin-pretreated sity was dependent on the concentration of FITC-crocollagen (10 min, then washed out) was also measured (l). All experividisin added (Fig. 9) . On the other hand, there was ments were carried out in triplicate and data were expressed as no significant fluorescence increase if FITC-BSA was means of triplicate results. Control efficiency of the adhesion of plateused instead of FITC-crovidisin (Fig. 9) . Even after the lets to collagen and fibrinogen in the absence of inhibitors was 5.9 and 7.2% of total platelets added into the well, respectively. extensive wash (10 times) with PBS, FITC-crovidisin firmly bound to collagen fibers as evidenced by the at the upstream step, whereas crotavirin blocks the downstream of platelet aggregation caused by collagen. strong fluorescence intensity of collagen (data not shown).
Interaction of FITC-Crovidisin with Collagen
Platelets did not adhere to collagen in the presence of crovidisin (Fig. 9 ), confirming our inference that crovidisin interferes with the initial interaction between Partial Sequence Analysis of Crovidisin platelets and collagen. However, two possibilities exist The HPLC peptide map of the trypsin-digested crovi-that crovidisin may affect collagen-mediated platelet disin fragments was shown in Fig. 10 and the amino functions by acting on either collagen or collagen recepacid sequences of some tryptic peptides of crovidisin tor expressed on the platelet membrane. We did not were shown in Fig. 11 . These amino acid sequences detect any binding of crovidisin to platelets (data not of crovidisin show almost complete identity (50 of 51 shown). The inhibitory effect of crovidisin on platelet residues) to that of catrocollastatin comparing their aggregation was surmountable by a second challenge partial sequences of the digested fragments. Catrocol-of collagen, indicating that collagen receptors on the lastatin, a collagen antagonist derived from C. atrox platelet membrane remain accessible to collagen after venom, is a multidomain molecule composed of a N-crovidisin treatment. Furthermore, after pretreatment terminal domain, a metalloproteinase domain, a disin-of collagen with crovidisin followed by successive PBS tegrin-like domain, and a cysteine-rich C-terminal do-washes, the subsequent platelet-collagen interaction main (16) . Crovidisin differs from catrocollastatin only was still blocked, indicating that crovidisin may diin a proline residue in place of serine at position 576 rectly bind to collagen fibers in a rather irreversible in the C-terminal domain of catrocollastatin (Fig. 11) . manner (Fig. 9 ). As shown in Fig. 9 , FITC-crovidisin directly bound to collagen fibers as the fluorescence DISCUSSION intensity increased progressively as the concentration In the present study, a platelet aggregation inhibitor existing in snake (C. viridis) venom has been isolated and characterized to be a selective inhibitor of collageninduced platelet aggregation. This novel inhibitor, named crovidisin, is a 53-kDa protein which selectively blocked platelet aggregation elicited by collagen in a dose-dependent manner without affecting those triggered by other inducers such as thrombin, ADP, and sodium arachidonate (Figs. 5 and 6 ). Crovidisin inhibited not only aggregation but also the activating processes, including granule release, thromboxane formation, and increase of cytosolic free calcium of platelets in response to collagen. This inhibitory profile of crovidisin is different from that of crotavirin, another platelet aggregation inhibitor occurring in the same venom the activating process, suggesting that crovidisin acts of this probe increased. On the other hand, FITC-BSA wall causing hemorrhagic effects (31). The metal ion, especially zinc ion, in the active site of these proteindid not significantly bind to collagen. In addition, the interaction between crovidisin and collagen was in a ases is required for enzymatic activity and in some cases it is important for maintaining the native strucdivalent cation-independent manner because EDTA (2 mM) did not attenuate crovidisin binding to collagen, ture of the protein (31, 32). Since crovidisin was proposed to contain the so-called metalloproteinase doand the inhibitory activity of crovidisin on the adhesion of platelets to collagen was not affected by EDTA when main like catrocollastatin, it is reasonable to infer that this enzymatic activity may contribute to its inhibitory collagen was pretreated with this inhibitor (data not shown). Although its mechanism of action is different action. But our data revealed that it is unlikely in this case. First, a prolonged incubation of collagen with from that of 6F1, a monoclonal antibody raised against glycoprotein Ia/IIa (also called a2b1 or VLA2), crovi-crovidisin did not enhance its inhibitory effect on platelet adhesion. Second, EDTA did not block crovidisin's disin like 6F1 predominantly blocked platelet-collagen interaction without affecting GPIIb/IIIa-mediated inhibitory activity on the interaction between platelets and collagen. Third, the binding of crovidisin to collaplatelet-fibrinogen interaction that was markedly inhibited by 7E3, a monoclonal antibody to GPIIb/IIIa, gen was not affected by EDTA (data not shown).
In addition to the normal functions, collagen may and by a snake venom-derived GPIIb/IIIa antagonist, crotavirin. This indicates that crovidisin selectively in-serve as a pathological mediator through its interaction with cells such as in arterial thrombosis (33) and in terferes with the interaction between collagen and platelets through binding to collagen fibers. However, proliferative vitreoretinopathy which is the leading cause of failure of retinal reattachment surgery (34) . whether crovidisin binds to denatured collagen type I or other types of collagen still remains to be elucidated. Much effort has been devoted to understanding the mechanism regarding the collagen-cell interaction Both molecular weight and amino acid composition of crovidisin were shown to be similar to those of catro-and designing inhibitors to block the interaction between collagen and cells. As a protein that can associcollastatin, a snake venom protein from C. atrox, which also inhibits platelet aggregation and adhesion to ate with collagen to prevent collagen-mediated platelet adhesion and aggregation, crovidisin may become an collagen. The cDNA-derived amino acid sequence of catrocollastatin reveals that this inhibitor contains an N-useful tool in elucidating the mechanism of collagencell interaction at a molecular level. Furthermore, in terminal domain, a metalloproteinase domain, a disintegrin-like domain, and a cysteine-rich C-terminal our unpublished data, crovidisin dose-dependently blocked the aggregation of human washed platelets domain (16) . From the partial amino acid sequence analysis, crovidisin was found to contain some identical caused by trimucytin, a snake venom protein which has been demonstrated to cause activation as well as sequences that appeared in the metalloproteinase domain, disintegrin-like domain, and C-terminal domain aggregation of platelets by acting as a GPIa/IIa agonist (4) . Further study on the interaction of crovidisin-colof catrocollastatin (Fig. 11) . These results indicate that crovidisin may be a multidomain molecule composed of lagen and crovidisin-trimucytin at a molecular level may provide a new avenue for developing inhibitors to four different domains like catrocollastatin. Jararhagin is another inhibitor of collagen-induced platelet aggre-prevent collagen-mediated detrimental effects. gation purified from Bothrops jararaca snake venom whose amino acid sequence shows high homology to
